{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ALMS",
  "name": "Alumis Inc.",
  "url": "https://orbyd.app/dossiers/ALMS/",
  "json_url": "https://orbyd.app/dossiers/ALMS.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Best-in-class oral TYK2 story sitting near 52-week highs (~$28) as the market waits on the Q3 2026 LUMUS Phase 2b lupus topline — the binary that either re-rates envudeucitinib into a multi-billion indication or caps it as a psoriasis-only pill. The calendar is now inside the readout window, so the print is undated and headline risk is any-session.",
  "invalidation_trigger": "A weekly close below $22 breaks the April–June rising base that carried the stock from ~$20 to ~$28; secondarily, a LUMUS Phase 2b lupus primary-endpoint miss caps it as a psoriasis-only name and round-trips a large slice of the post-January re-rate.",
  "catalyst_date": "2026-09-15",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology",
    "precision-biotech-therapeutics",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Watch competitor read-across: Takeda zasocitinib and BMS Sotyktu data can reprice ALMS independent of its own pipeline.",
    "LUMUS Phase 2b SLE topline is anticipated Q3 2026 and NOT date-certain — enrollment is complete, so treat any session from late July onward as potential binary headline risk. The 2026-09-15 catalyst_date is a mid-quarter placeholder, not a confirmed date.",
    "Now INSIDE the readout quarter: a fresh entry near 52-week highs ahead of an undated, imminent Phase 2b binary is a coin-flip — probe-size or stand aside until the name bases lower or the topline clears. Conviction downgraded from MEDIUM as the window went live.",
    "Psoriasis leg is de-risked: ONWARD1/ONWARD2 Phase 3 hit all endpoints (full data 2026-03-28, PASI 100 41.0%/39.5% at Week 24); NDA targeted H2/Q4 2026 (reaffirmed 2026-05-14). Cash $569.5M at 2026-03-31, runway to Q4 2027 — no forced raise into either catalyst.",
    "Watch competitor read-across: Takeda zasocitinib and BMS Sotyktu (deucravacitinib) data can reprice ALMS independent of its own pipeline.",
    "Theme tag 'oncology-immunology' is a registry misnomer — Alumis is pure immunology/autoimmune (oral TYK2 inhibitor for psoriasis and lupus), with no oncology program.",
    "Q2 2026 earnings likely mid-August (est. ~2026-08-13, not confirmed) — a hard-dated checkpoint that typically reaffirms LUMUS/NDA timing; not thesis-driving for a pre-revenue name.",
    "Beta of -0.71 is a January-spike artifact, not a genuine macro hedge — do not treat the name as defensive."
  ],
  "body_markdown": "## Current Thesis\nAlumis is a clinical-stage immunology company whose entire equity value runs through one molecule: envudeucitinib (ESK-001), a next-generation, highly selective oral TYK2 inhibitor for psoriasis and lupus. The narrative detonated on 2026-01-06 when Phase 3 psoriasis topline moved the stock +95.31% in a single session, and it has since ground from a sub-$10 pre-catalyst base to ~$28 (up ~625% over twelve months into July 24, 2026). The psoriasis leg is now largely de-risked — full ONWARD1/ONWARD2 data on 2026-03-28 showed PASI 90 of 68.0%/62.1% and PASI 100 of 41.0%/39.5% at Week 24 across 1,700+ patients, cross-trial the leading skin clearance among next-generation oral therapies. What an investor is buying at this price is the next binary: the LUMUS Phase 2b topline in systemic lupus (SLE), anticipated Q3 2026 with enrollment complete. The calendar has now rolled inside that window, so the readout is undated and imminent. A clean hit re-rates the platform beyond dermatology into a multi-billion indication; a primary-endpoint miss caps the name as one more oral psoriasis pill in a crowded field. This is an event, not a trend to chase.\n\n## Bull Case\n- **Best-in-class Phase 3 efficacy (full data 2026-03-28):** PASI 90 68.0%/62.1% and PASI 100 41.0%/39.5% at Week 24 across ONWARD1/ONWARD2; management frames this as leading skin clearance versus next-gen oral peers including the entrenched incumbent Sotyktu.\n- **Proven narrative velocity:** the 2026-01-06 topline (PASI 75 74%, sPGA 0/1 59% at Week 16) produced a +95.31% single-day move — the market has demonstrated it pays up for this readout profile.\n- **Asymmetric lupus optionality:** the LUMUS Phase 2b SLE topline is anticipated Q3 2026 with enrollment complete. TYK2 sits on the type-I interferon axis central to lupus biology; a positive read opens a large indication no oral TYK2 has yet cracked.\n- **Funded through both catalysts:** $569.5M cash and marketable securities at 2026-03-31, runway stated through Q4 2027 — covers the psoriasis NDA and the lupus readout with no forced raise.\n- **NDA on the calendar:** envudeucitinib plaque-psoriasis NDA targeted for H2/Q4 2026, reaffirmed on the 2026-05-14 Q1 call — a step from clinical asset toward commercial.\n- **Sell-side still lifting:** consensus Strong Buy, average price target ~$40 (up from ~$38.50 in early July); HC Wainwright raised its target to $40 from $20 with a Buy — targets rising is the signature of a narrative the Street hasn't fully priced.\n\n## Bear Case\n- **Crowded oral autoimmune field:** Sotyktu (BMS deucravacitinib) is the established oral TYK2, and Takeda's zasocitinib is advancing a competing next-gen molecule — a cross-trial efficacy edge does not guarantee formulary share or pricing power.\n- **Pure cash burn:** Q1 2026 (reported 2026-05-14) showed a net loss of $93.1M with revenue collapsing to $1.7M from $17.4M a year prior; no meaningful product revenue before 2027 at the earliest.\n- **Priced near the range top:** ~$28 against a 52-week range of $3.25–$31.35, roughly 10% under the high after a ~625% twelve-month run — a great deal of good news is embedded ahead of the lupus print.\n- **LUMUS is Phase 2b in the hardest indication:** SLE is the immunology graveyard, and a primary-endpoint miss could round-trip a large slice of the post-January re-rate in a single gap.\n- **Serial issuance into strength:** a $17.00 offering (20.3M shares) closed 2026-01-09 and roughly $345.1M gross was raised around the March results — the market gets tapped when the tape is strong.\n- **Reverse-merger overhang:** the ACELYRIN combination (closed 2025-05-21, $238.1M, 48.65M shares issued) inflated the share count into the current move.\n\n## Setup & Price Structure\n- Last at $28.00 (July 24, 2026 close, -1.06% on the day, intraday range $26.94–$28.51); market cap ~$3.57B on ~127.5M shares.\n- 52-week range $3.25–$31.35: the stock sits at the top of a multi-month base, ~10% below the $31.35 high, which now functions as overhead supply and the breakout trigger.\n- The April–June advance built a rising base from ~$20 to ~$28; a weekly close below $22 breaks that structure.\n- Structurally clean but event-loaded: buying near 52-week highs ahead of an undated, now-live binary is a coin-flip on the readout. The disciplined stance is a small probe or standing aside until the name either bases lower or the topline clears — an accelerating tape does not mitigate a Phase 2b gap.\n\n## Catalyst Calendar (next 30 days)\n\n- **LUMUS Phase 2b SLE topline — anticipated Q3 2026 (undated; ~2026-09-15 mid-quarter placeholder):** enrollment complete; the window is now live, so any session from late July onward carries binary headline risk. This is the dominant catalyst.\n- **Q2 2026 earnings — est. ~2026-08-13 (not confirmed):** a hard-dated checkpoint where management typically reaffirms the LUMUS and NDA timelines; not thesis-driving on its own for a pre-revenue name.\n- **Competitor read-across:** any BMS Sotyktu or Takeda zasocitinib data landing in the window can reprice ALMS independent of its own pipeline.\n\n## Elapsed catalysts\n\n- **Envudeucitinib psoriasis NDA submission — targeted H2/Q4 2026** (reaffirmed 2026-05-14): timing updates likely at the next print. *(passed 87d ago)*\n\n## What Would Change Our Mind\n- **Bull confirmation:** LUMUS hits the SLE primary endpoint — the platform re-rates beyond dermatology and a multi-billion TAM opens; a clean beat that also carries price through $31.35 on volume converts the setup from event-bet to trend-follow.\n- **Thesis break:** a weekly close below $22 loses the April–June rising base; a LUMUS primary-endpoint miss caps the name as a psoriasis-only pill and would round-trip a large slice of the post-January gains. A theme flip toward SATURATED — if Takeda or BMS data undercuts the differentiation — would compound either.\n- Because the readout is undated and imminent, invalidation here is event-driven first and level-driven second: a fresh position near highs is exposed to a binary gap in both directions before any moving average is tested.\n\n## Correlation Notes\n- **Single-molecule idiosyncratic risk:** the whole equity story is envudeucitinib, so fundamental correlation to the broad index is low. The reported beta of -0.71 is an artifact of the isolated January spike, not a genuine macro hedge — do not treat it as defensive.\n- **Peer read-across dominates the tape between prints:** BMS (Sotyktu) and Takeda (zasocitinib) TYK2 data can move ALMS independent of its own pipeline.\n- **Biotech beta:** the name trades with XBI/IBB on risk-on/risk-off and the rate regime for long-duration clinical assets, but through Q3 the LUMUS readout will swamp every other input.",
  "first_seen": "2026-07-07",
  "last_analyzed": "2026-07-26T11:34:44+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}